Search clinical trials for: recombinant human erythropoietin (rhEpo)

Total 1270 results

Green Cross Corporation
ICON Clinical Research

Terminated

Safety Study of MG1102 in Patients With Solid Tumors

Solid Tumors

Korea, Republic of
Protalix

Completed

Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients

Gaucher Disease

Israel
Patricia I. Dickson, M.D.
The Ryan Foundation

Terminated

Extension Study of Intrathecal Enzyme Replacement Therapy for MPS I

Mucopolysaccharidosis I | Scheie Syndrome | Lysosomal Storage Disease | Spinal Cord Compression | Hurler-Scheie Syndrome

Finland, United States
NHS Greater Glasgow and Clyde

Completed

Efficacy and Safety of R-hLH (Luveris ®) Priming Prior to R-HFSH Treatment in Infertile Women Undergoing IVF-ET

Infertility

Denmark, France, United Kingdom
AM-Pharma

Terminated

(Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI

Acute Kidney Injury Due to Sepsis

Belgium, Spain, United States, Austria, Denmark, France, United Kingdom, Finland, New Zealand, Australia, Germany, Canada, Netherlands, Ireland, Japan
Zensun Sci. & Tech. Co., Ltd.

Active, not recruiting

Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure

Chronic Systolic Heart Failure

China
Shire

Completed

Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD) (IDEAMLD)

Metachromatic Leukodystrophy (MLD)

Australia, Denmark, Japan, France, Germany
The First Affiliated Hospital of Guangzhou Medical...

Withdrawn

Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19

COVID-19

China
University of Miami
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Effects of Human Leptin Replacement

Obesity | Diabetes | Metabolic Syndrome

United States
Daiichi Sankyo, Inc.

Completed

Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure

Heart Failure, Congestive | Heart Decompensation | Left Ventricular Failure | Myocardiopathies | Systolic or Diastolic Left Ventricular Dysfunction

United States, Canada
Genzyme, a Sanofi Company

Completed

High Dose or High Dose Frequency Study of Alglucosidase Alfa

Glycogen Storage Disease Type II (GSD-II) | Pompe Disease | Glycogenesis 2 Acid Maltase Deficiency

United States, Canada, Australia
TNO
Alloksys Life Sciences B.V.

Completed

Microdose and First-In-Human (FIH) Study of Recombinant Human Placental Alkaline Phosphatase (hRESCAP)

Healthy

Netherlands
University of Zurich

Completed

Intravenous Treatment of Anemia in Pregnancy

Anemia
Second Affiliated Hospital, School of Medicine,...

Recruiting

Effect of the Combined Programme on Perioperative Anaemia（CPPA）

Cardiac Surgery | Iron Deficiency Anemia | Patient Blood Management

China
Shire

Completed

Long-term Metazym Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)

Late Infantile Metachromatic Leukodystrophy

Denmark
Asahi Kasei Pharma America Corporation

Completed

Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy

Severe Sepsis | Coagulopathy

Korea, Republic of, United States, Taiwan, Netherlands, United Kingdom, Australia, Canada, Belgium, Israel, Spain, New Zealand, France, Brazil, India, Argentina, Bulgaria, Croatia, Czechia, Finland, Germany, Hungary, Peru, Russian Federation and more
BioMarin Pharmaceutical

Completed

BMN 110 Phase 3B in Australian Patients (MOR-AUS)

Mucopolysaccharidosis IVA (Morquio A Syndrome)

Australia
Asahi Kasei Pharma America Corporation

Withdrawn

The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy (Scarlet2)

Sepsis and Coagulopathy
AB2 Bio Ltd.

Completed

Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease

Still's Disease, Adult-Onset

Germany, France, Switzerland
Protalix

Completed

An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112

Gaucher Disease

Israel
Novo Nordisk A/S

Withdrawn

Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects

Healthy | Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B
Sichuan Clover Biopharmaceuticals, Inc.

Terminated

A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis

Peritoneal Carcinomatosis

China
Clover Biopharmaceuticals AUS Pty Ltd

Completed

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Pleural Effusions

Malignant Pleural Effusions

Australia
Novo Nordisk A/S

Completed

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation

Acquired Bleeding Disorder | Bleeding During/Following Surgery

Israel, Sweden, United Kingdom, Germany, Switzerland, France, Spain, Italy, Thailand, Denmark, United States, Poland, Finland, Singapore, Australia, Austria
Merck KGaA, Darmstadt, Germany

Completed

r-hLIF for Improving Embryo Implantation in IVF

Infertility Implantation Failure
Merck KGaA, Darmstadt, Germany

Completed

A Multicentre, Randomised, Double-blind, Placebo-controlled Proof of Concept Study to Compare the Efficacy and Safety of r-hLIF (Emfilermin) for Improving Embryo Implantation Following in Vitro Fertilization (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure

Infertility Implantation Failure
Zhejiang Cancer Hospital

Not yet recruiting

H101 Combined With Camrelizumab for Recurrent Cervical Cancer

Uterine Cervical Neoplasms | Oncolytic Virotherapy | Camrelizumab

China
BioAegis Therapeutics Inc.

Completed

Rhu-pGSN for Severe Covid-19 Pneumonia

Sars-CoV2

Romania, Spain
GeneScience Pharmaceuticals Co., Ltd.
The First Affiliated Hospital with Nanjing Medical University; Tongji Hospital and other collaborators

Active, not recruiting

A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature

Dwarfism

China
Sichuan Clover Biopharmaceuticals, Inc.

Completed

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites

Malignant Ascites

China
Clover Biopharmaceuticals AUS Pty Ltd

Completed

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies

Peritoneal Malignancies

Australia
Merck Sharp & Dohme LLC

Completed

Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)

Measles | Rubella | Mumps | Varicella
Novo Nordisk A/S

Terminated

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation

Acquired Bleeding Disorder | Bleeding During/Following Surgery

United States
Novo Nordisk A/S

Completed

Use of Activated Recombinant FVII in Spinal Surgery

Spinal Fusion | Acquired Bleeding Disorder

United States
Novo Nordisk A/S

Completed

Factor VIIa in Acute Intracerebral Haemorrhage

Acquired Bleeding Disorder | Intracerebral Haemorrhage

Japan
Novo Nordisk A/S

Completed

A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers

Healthy | Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Stem Cell Factor Medication for Aplastic Anemia

Pancytopenia | Aplastic Anemia

United States
The First Hospital of Jilin University

Completed

Safety and Tolerance Study of Recombinant Human Albumin Injection in Healthy Subjects.

Ascites

China
Beijing Tongren Hospital

Recruiting

The Phase I Study of Recombinant Human Nerve Growth Factor Injection

Injury of Optic Nerve

China
Protgen Ltd

Completed

Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects

Hepatic Ascites

China
Columbia University
Tercica

Terminated

Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors

Growth Hormone Deficiency

United States
Martin, Paul
National Cancer Institute (NCI)

Completed

Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer

Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma and other conditions

United States
Shandong University
The Second Hospital of Hebei Medical University; RenJi Hospital

Not yet recruiting

Effect of Growth Hormone Injection on the IVF/ICSI Outcome of Patients With Poor Ovarian Reserve.

Poor Ovarian Reserve
Ultragenyx Pharmaceutical Inc

Available

Expanded Access to Mepsevii

Sly Syndrome | Mucopolysaccharidosis VII | MPS VII
Chiesi Farmaceutici S.p.A.

Available

Expanded Access to Velmanase Alfa

Alpha-Mannosidosis
Phoenix Tissue Repair, Inc.

Completed

A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB) (PTR-01-001)

Recessive Dystrophic Epidermolysis Bullosa

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.

Hemophilia A

China
Novo Nordisk A/S

Completed

Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
Jon Simmons
University of South Alabama

Recruiting

Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure (DAMPENCOVID)

Covid19

United States
National Center for Research Resources (NCRR)

Completed

Continuously Infused Intracerebral (IC) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) for the Treatment of Idiopathic Parkinson's Disease

Parkinson Disease

United States

Search clinical trials for: recombinant human erythropoietin (rhEpo)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations